🔎 Trials Near Me

Utama › Liposarcoma › New Jersey

Kajian klinikal Liposarcoma di New Jersey

5 kajian untuk Liposarcoma sedang mencari peserta di lokasi di New Jersey.

Bandar di New Jersey

Teks kajian rasmi (Bahasa Inggeris)

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Bergen, Montvale
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06422806

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06843967

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  • Cooper Hospital University Medical Center, Camden
  • HMH-Hackensack University Medical Center, Hackensack
  • Jersey Shore University Medical Center, Neptune City
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT04031677

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Hackensack University Medical Center, Hackensack
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07089992

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.